Homocysteine and Digestive Tract Cancer Risk: A Dose-Response Meta-Analysis

Jun Xu,1 Xin Zhao,2 Shanwen Sun,1 Peng Ni,1 Chujun Li,3 Anjing Ren,1 Wei Wang,4 and Lingjun Zhu1

1Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
2Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
3Department of Plastic and Burns Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
4Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Correspondence should be addressed to Wei Wang; wangwei-doctor@163.com and Lingjun Zhu; zhulingjun@njmu.edu.cn

Received 1 April 2018; Revised 14 October 2018; Accepted 11 November 2018; Published 18 December 2018

Academic Editor: Ozkan Kanat

Copyright © 2018 Jun Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Homocysteine, a key component in one-carbon metabolism, is of great importance in remethylation. Many epidemiologic studies have assessed the association between homocysteine and risk of digestive tract cancer, but the results are inconsistent. Objective. The objective of our meta-analysis is to assess the association between homocysteine and digestive tract cancer risk. Methods. Comprehensive searches were performed on the PubMed, Embase, Cochrane, and Web of Science databases up to September 25, 2018, to identify relevant studies. Thirteen studies were included in the meta-analysis. Odds ratios (ORs) and their corresponding 95% confidence intervals (95% CIs) were used to estimate the strength of the relationship between homocysteine and the risk of digestive tract cancer. Results. The pooled OR of digestive tract cancer risk for patients with the highest categories of blood homocysteine levels versus the lowest categories was 1.27 (95% CI, 1.15, 1.39) with no significant heterogeneity observed (P = 0.798, I² = 0.0%). Moreover, the dose-response analysis revealed that each 5 𝜇mol/L increase in homocysteine increased the incidence of digestive tract cancer by 7%. Conclusion. Generally, our results indicated that elevated homocysteine was associated with higher risk of digestive tract cancer. That is, homocysteine concentration may be a potential biomarker for occurrence of digestive tract cancer.

1. Introduction

Digestive tract cancers, which refer to malignant diseases of the gastrointestinal tract and mainly including esophageal, gastric, and colorectal cancers, are still major public health burdens. According to Globocan 2012 estimates, the standardized incidences of colorectal cancer, stomach cancer, and esophageal cancer were the 3rd, 5th, and 8th most common, respectively, of all tumors, making up 19.7 percent of new cancer cases. Gastric cancer, ranked as the third leading cause of cancer death, results in 723,000 deaths in both sexes annually all over the world. In total, digestive tract cancer constitutes 22.2 percent of the mortality due to cancer, leading to 1,817,000 cases of cancer death every year [1].

Previous studies have found that DNA methylation, which varies in the development of many cancer types, has a link to cancer [2]. Hypermethylation or hypomethylation, in which one-carbon metabolites play an important role, can be observed in a wide variety of malignancies, including gastric, esophageal, and colorectal cancers [3, 4]. If substances that reflect cellular methylation status can be found, these cancers could be found in the early stages and millions of people could cheat death and live longer lives. One-carbon metabolic reactions mainly include two biological processes: the synthesis of purines and pyrimidines, which are necessary for DNA replication and repair, and the synthesis of S-adenosylmethionine (SAM), a methyl group donor for a number of methylation reactions, including DNA, RNA, and protein methylation. Homocysteine, as the intersection of the methylation, remethylation and transsulfuration pathways, is an important component in the one-carbon metabolism. S-adenosylhomocysteine produces...
homocysteine catalyzed by S-adenosylhomocysteine hydrolase, which is a reversible reaction. Therefore, homocysteine is intrinsically linked to cellular methylation status. Methionine synthase produces methionine by remethylation of homocysteine, using the methyl group from betaine, or from 5-methyltetrahydrofolate, derived from the metabolism of 5,10-methylene tetrahydrofolate by 5,10-methylene tetrahydrofolate reductase. In the transsulfuration pathway, homocysteine produces cystathionine, the precursor for cysteine biosynthesis, catalyzed by vitamin B6-dependent cystathionine β-synthase [5]. The pathway which involves the transamination of homocysteine to form methionine can be affected by folic acid and vitamin B12 [6]. Deficiencies of folate and vitamin B12 can first block the reaction of homocysteine remethylation and, second, block homocysteine catabolism because of the reduced synthesis of SAM [7]. The relationship between folic acid and digestive cancer has been discussed by various studies, but epidemiological data are inconsistent [8–12]. Additionally, many studies have focused on the influence of the B vitamins on the risk of digestive tract cancer [13]. Studies found that total homocysteine concentration can represent one-carbon metabolism related nutrients, especially folic acid and B vitamins [14].

Homocysteine has been widely studied in terms of cardiovascular disease and has been recognized as a potential risk factor for stroke, coronary vascular disease, ischemic heart disease, and other vascular occlusive diseases [15, 16]. Besides, the effect of homocysteine on cancer has also been discussed. So far, several epidemiologic studies have also assessed the relation of homocysteine to the incidence of digestive tract cancer, but the results are inconsistent. For example, data from Lina Wang et al. [17] and Miller et al. [18] showed that an increased occurrence of digestive tract cancer was observed in people with higher levels of homocysteine than in those with lower levels. However, some studies on this topic showed a nonsignificant increase in the risk of digestive tract cancer in populations with the highest levels of homocysteine [19, 20]. One meta-analysis performed by Collin et al. demonstrated the relationship between blood total homocysteine and prostate cancer [21]. Another meta-analysis written by Xu et al. found that higher blood homocysteine levels increased gastric cancer risk [22].

Based on the central role of homocysteine in carbon metabolism, its predictive role in cardiovascular disease, and the inconsistency of existing epidemiologic studies and inadequate statistical power in many primary studies, we chose to study the role of homocysteine in digestive tract cancers. The meta-analysis was conducted to assess the evidence from the literature on the relationship between blood levels of homocysteine and the risk of digestive tract cancers and to further evaluate the dose-response relationship. We hope that we can provide a basis for the use of homocysteine as a tumor marker of digestive tract cancers in the future.

2. Materials and Methods

2.1. Search Strategy. We conducted a comprehensive, computerized literature search of the PubMed, Embase, Cochrane, and Web of Science databases for relevant epidemiologic studies with the aim of investigating the connection between homocysteine and digestive tract cancers published on September 25, 2018. The key words used were as follows: (1) gastrointestinal neoplasms, colorectal neoplasms, colorectal carcinoma, colorectal cancer, colonic neoplasms, colonic carcinoma, colonic cancer, colon neoplasms, colon cancer, rectal neoplasms, rectal carcinoma, rectal cancer, rectum neoplasms, rectum cancer, rectum carcinoma, esophageal neoplasms, esophageal cancer, esophageal tumor, esophageal carcinoma, gastric neoplasms, gastric cancer, gastric tumor, gastric carcinoma, stomach neoplasms, stomach cancer, stomach tumor, and stomach carcinoma; (2) homocysteine, 2-amino-4-mercaptopbutyric acid, hcy, thcy, and hyperhomocysteinemia. In addition, references from the relevant original reports were also scrutinized and hand-searched. No restrictions were imposed. We also made efforts to contact the authors of the primary studies for additional information. Our meta-analysis did not include unpublished reports.

2.2. Study Selection. Studies were recognized as eligible for our analysis if they met the following criteria: (1) the study design was a case-control or cohort study and investigated the association between homocysteine and digestive tract cancer incidence; (2) articles were written in English; (3) two comparison groups (cancer group vs. control group) were included in the study; (4) the outcome of this review, the incidence risk data of univariate and/or multivariate analyses presented as OR, had a 95% CI when comparing the highest levels of homocysteine with the lowest levels.

The exclusion criteria were as follows: (1) the articles only composed of an overview and summary (without data); (2) animal study; (3) the same population in another study; and (4) studies with incomplete data.

2.3. Data Extraction. The two authors independently extracted all the data according to the selection criteria and reached a consensus on all projects. If there was a disagreement, another author would reevaluate these articles. All data was extracted using a standardized data-collection form. Study features were recorded as follows: (1) name of first author and publication year; (2) cancer type; (3) the location of the study conducted and study design; (4) the number of cases and controls; (5) method of measurement; (6) gender and age of cases; (7) source of controls; (8) ORs from the most fully adjusted model for the highest homocysteine compared with the lowest homocysteine and their corresponding 95% CIs; and (9) confounders adjusted for in multivariate analysis. Homocysteine was expressed uniformly as $\mu$mol/L.

We used a scale called the Newcastle-Ottawa-Scale (NOS) to assess the quality of eligible studies. According to the NOS, studies were evaluated according to 3 aspects, including selection, comparability, and measurement of exposure for case-control studies or outcome for cohort studies. The NOS scale ranges from zero to nine stars. A study with $\geq 6$ stars would be regarded as a high-quality study [31].
2.4. Statistical Analysis. Odds ratios and their corresponding 95% confidence intervals were used to measure the strength of the correlation between homocysteine and the risk of digestive cancer. The Q-test and the $I^2$ (inconsistency index) statistic were calculated to quantify the proportion of total variation attributable to heterogeneity between eligible studies [32]. Generally, $P < 0.05$ corresponded to heterogeneity across eligible studies, and a random-effects model (DerSimonian and Laird method) was appropriate to compute the summary risk estimates. Otherwise, the fixed-effects model (the Mantel-Haenszel method) was preferred. Moreover, $I^2$ values >50% represented strong heterogeneity between studies and $I^2$ values <25% suggested no significant heterogeneity [33]. We also conducted an influence analysis in which one study was omitted at a time and the rest were analyzed to investigate the effect of a single study on the overall result. The evidence of potential publication bias was assessed using Begg's funnel plot and Egger's linear regression test and $P < 0.05$ represented significant publication bias [34, 35]. All statistical analyses were performed using Stata software (version 12.0, USA).

To estimate the trend in correlated OR with the elevated concentration of homocysteine, we conducted a dose-response analysis using the method recommended by Greenland and Longnecker [36] and the publicly available Stata code written by Orsini et al. [37]. At least 3 quantitative exposure categories of homocysteine with corresponding median or mean values of homocysteine for each category, distributions of cases and noncases, and ORs and its corresponding 95% CIs were necessary for the analysis. Supposing that studies did not report median or mean values of concentration, we used the midpoint of each category. If the highest or lowest category was open-ended, the midpoint of each category was estimated by assuming that the width of the category was the same as the next adjacent category. The dose-response results are presented for a 5μmol/L increment.

3. Results

3.1. Characteristics of the Studies. By the search strategy, a total of 792 citations were obtained from the PubMed, Embase, Cochrane, and Web of Science databases, of which 37 eligible studies were considered of potential value; then, we retrieved the full text for further evaluation. According to inclusion criteria, 24 of the 37 articles were subsequently excluded from the meta-analysis (11 did not report OR and/or 95% CI, 7 were not written in English, 2 were conference articles, 2 reported data on the same population, and 2 lacked information for detailed analysis). Finally, 13 articles [8, 17–20, 23–30] (4 case-control and 9 nested case-control studies) met our inclusion criteria (Figure 1). Details of these studies are presented in Table 1.

3.2. Overall and Subgroup Results. The multivariable-adjusted ORs for each study and all studies combined for the highest compared with the lowest categories of homocysteine level are shown in Figure 2. The pooled OR of digestive cancer for the highest compared with the lowest categories of blood homocysteine level was $1.27$ (95% CI, 1.15, 1.39) with no significant heterogeneity observed ($P = 0.798$, $I^2 = 0.00$). Thus, we utilized fixed-effects models to analyze the association. Significantly increased incidence of digestive tract cancer was observed in patients with high homocysteine levels compared with those with low levels, from the data.

Firstly, in the subgroup analysis of study design, the OR was $1.16$ (95% CI, 0.99–1.37) for nested case-control studies and $1.33$ (95% CI, 1.18–1.49) for case-control studies. We further analyzed the results by study location: studies conducted in Asia (OR = 1.33; 95% CI: 1.18, 1.49) and America (OR = 1.38; 95% CI: 1.05, 1.80) indicated that higher homocysteine was associated with the increased occurrence of digestive cancer in people living in Asia and America. However, we did not see this effect in Europeans (OR = 1.06; 95% CI: 0.87, 1.30). Additionally, the subgroup analysis of cancer type suggested that colorectal cancer risk was positively associated with homocysteine levels (OR = 1.27; 95% CI: 1.14, 1.41), while the relationship became weaker in esophageal cancer (OR = 1.31; 95% CI: 0.89, 1.93) and gastric cancer (OR = 1.27; 95% CI: 0.98, 1.64). Of the 13 articles, 3 articles measured homocysteine in serum (OR = 1.26; 95% CI: 0.91, 1.74), and 10 articles measured homocysteine in plasma (OR = 1.27; 95% CI: 1.15, 1.40). Additionally, in the subgroup analysis of method of measurement, the positive association was still significant in studies using HPLC (OR = 1.29; 95% CI: 1.6, 1.44), while the association was not significant in studies using GC-MS and FPIA. Details can be seen in Table 2.

3.3. Dose-Response Analysis. Only 5 articles [17, 20, 25, 28, 29] composed of 6 comparisons from all 13 studies were eligible for exploring the dose-response relationship between the concentration of homocysteine and digestive cancer risk. The summary OR per 5μmol/L increase in homocysteine was 1.07 (95% CI, 1.01 to 1.19) (Figure 3) which revealed that each 5μmol/L increase in homocysteine was associated with a 7% higher risk of digestive cancer occurrence.

3.4. Influence Analysis. To assess the stability of the results, we performed an influence analysis in which one study was omitted at a time each term and we calculated the pooled ORs for the rest of the studies. The analysis showed that the result was mostly affected by the study of F.-F. Chiang et al. (Figure 5). After excluding the study, the pooled OR was 1.24 (95% CI, 1.08-1.43), suggesting there were no changes in the direction of the effect which indicated good stability of our meta-analysis.

3.5. Publication Bias Analysis. Begg’s funnel plot and Egger’s test were conducted to evaluate the publication bias of the studies included. The shape of the funnel plots seemed symmetrical (Figure 4) and the $P$ value of Egger’s test was 0.59 ($P > 0.05$), which indicated that there was no existence of publication bias.

4. Discussion

On the basis of the pooled OR of our meta-analysis, people with higher homocysteine were more likely to suffer from
digestive tract cancer. According to the influence analysis, we can see that after removing the study of F.-F. Chiang et al., the pooled OR was changed most greatly, but the trend did not change, which indicated the stability of our result. The rest of the article included in our analysis classified the level of homocysteine by three or more categories, but the study of F.-F. Chiang et al. divided homocysteine levels into two categories (higher and lower), which may be the reason why it had significant influence on the pooled results. Moreover, the dose-response analysis further demonstrated the positive effect of homocysteine on digestive tract cancer: each 5μmol/L increase in concentration of homocysteine enhanced the chance of developing digestive cancer by 7%.

When stratified by study design, the positive association between homocysteine and digestive cancer risk was only seen in case-control studies and was weaker in nested case-control studies. Such results can be explained because it is difficult to distinguish the chronological sequence of exposure and occurrence of diseases because of the retrospective nature of case-control studies. Additionally, according to the subgroup analysis of location, elevated homocysteine levels seemed to have more predictive value for digestive cancer in people living in Asia and America. Moreover, in the separate analysis of cancer type, the positive association between homocysteine and digestive cancer risk was weaker in esophageal cancer and gastric cancer. The discrepancy in results could be attributed to the fact that there are limited studies on the relationship between homocysteine, the esophagus and gastric cancer risk, which affected the stability summary effects. Thus, more studies are needed to confirm our conclusion.

As we know, runaway gene expression and the unbalanced genome integrity whose major epigenetic mechanism is DNA methylation are considered causes of oncogenesis [38]. DNA methylation is the most relevant epigenetic feature in the clinic, in which a methyl group is covalently added to the cytosine of the CpG dinucleotide. Extensive hypomethylation and hypermethylation in normally unmethylated gene promoter CpG islands are considered to be the most commonly studied epigenetic alterations in cancer and affect the

**Figure 1:** Flow diagram of the study identification and selection.
Table 1: Main features of the included studies for the association between homocysteine and digestive tract cancer.

| First author, (year of publication) | Cancer type | Country; study design | Source of control | Case/Control | Method of measurement /Type of homocysteine | Gender | Median or mean age of (y) | Contrast (highest vs. lowest) (μmol/L) | Adjusted OR (95% CI) (highest vs. lowest) | Adjustment | Quality score |
|-------------------------------------|-------------|-----------------------|-------------------|-------------|--------------------------------------------|--------|--------------------------|----------------------------------|--------------------------------------|------------|--------------|
| I Kato et al. (1999) [23]           | colorectal cancer | US; Nested case-control | PB 105/523         | HPLC/ Serum | F 66.2 | Quartile ≥12.21 vs ≤7.9 | 1.72 (0.83-3.57) | Adjusted for family history of colorectal cancer, beer intake, prior occult blood testing and number of hours spent in sport activities in their early 30s. | 8          |  | 
| Pufuete et al. (2003) [24]         | colorectal cancer | England; case-control | HB 28/76          | FPIA/ Plasma | M/F 58 | Top third vs bottom third | 1.55 (0.21-11.16) | Adjusted for sex, age, body mass index, smoking, alcohol intake, MTHFR, MS, and CBS genotypes. Adjusted for body mass index, current smoking, recreational and occupational physical activity, and alcohol intake (alcohol data were available for approximately two thirds of subjects). | 7          |  | 
| Van Guelpen, Hultd in, Johansson et al. (2006) [19] | colorectal cancer | Sweden; Nested case-control | PB 226/437      | FPIA/ Plasma | M/F 59.8 | Quintile Q5 vs Q1 | 1.12 (0.63-1.99) | Adjusted for body mass index, current smoking, recreational and occupational physical activity, and alcohol intake (alcohol data were available for approximately two thirds of subjects). | 8          |  | 
| Stein Emil Vollset et al. (2007) [8] | gastric cancer | EPIC; Nested case-control | PB 245/631    | GC-MS/ Plasma | M/F 62.2 | Q5 vs Q1 | 0.87 (0.52-1.44) | Adjusted for Hp status, smoking, and energy in conditional logistic model with stratification on matched sets. | 8          |  | 
| Lina Wang et al. (2007) [17]       | gastric cancer | China; case-control | PB 306/615       | enzymatic biochemical/Plasma | M/F 60.6 | Quintile >13.6 vs ≤8.0 | 1.82 (1.20-2.75) | Adjusted for age, sex, smoking status, and alcohol consumption. | 7          |  | 
| Weinstein et al. (2008) [20]       | colorectal cancer | Finland; Nested case-control | PB 275/275       | HPLC/ Serum | M Colon:59.0 Rectal:38.0 | Quintile Q5 vs Q1 (18.8μmol/L vs 9.2μmol/L) | 1.22 (0.68-2.17) | Adjusted for age at randomization, body mass index, occupational and leisure physical activity, and intakes of vitamin D and iron. Adjusted for sex, ethnicity, study site, age at blood draw, fasting duration and date, time of blood draw, age at blood draw and hours of fasting prior to blood draw, hours of moderate or vigorous physical activity, processed meat, pack-years, BMI, ethanol, family history of colorectal cancer, history of colorectal cancer screening and plasma folate. | 8          |  | 
| Marchand et al. (2009) [25]        | colorectal cancer | US; Nested case-control | PB 224/411       | HPLC/ Plasma | M/F 70.5 | Quintile >11.8 vs ≤765 | 1.00 (0.56-1.79) | Adjusted for family history of colorectal cancer, beer intake, prior occult blood testing and number of hours spent in sport activities in their early 30s. | 8          |  |
| First author, (year of publication) | Cancer type | Country; study design | Source of control | Case/Control | Method of measurement / Type of homocysteine | Gender | Median or mean age of (y) | Contrast (highest vs. lowest) (μmol/L) | Adjusted OR (95% CI) (highest vs. lowest) | Adjustment | Quality score |
|------------------------------------|-------------|-----------------------|-------------------|--------------|---------------------------------|--------|-------------------------|------------------------------------------|------------------------------------------|-----------|---------------|
| Miller et al. (2013) [18]          | colorectal cancer | US; Nested case-control | PB | 988/988 | HPLC / Plasma | F | 67 | Quartile >9.85 vs ≤6.74 | 1.46 (1.05-2.04) | Adjusted for age, baseline BMI, ever had colonoscopy, smoking, physical activity (min/wk of moderate or strenuous activity), hormone replacement therapy, red blood cell folate, plasma vitamin B-12, and plasma pyridoxal-5'-phosphate. Adjusted for age, gender, body mass index, systolic blood pressure, creatinine, high sensitivity C-reactive protein, serum total cholesterol, smoking and drinking habits and B-vitamin supplement uses. | 8 |
| E.-F. Chiang et al. (2014) [26]    | colorectal cancer | China; case-control | HB | 168/188 | HPLC / Plasma | M/F | 60.8 | Higher vs lower | 1.29 (1.14-1.47) | Adjusted for age, gender, body mass index, systolic blood pressure, creatinine, high sensitivity C-reactive protein, serum total cholesterol, smoking and drinking habits and B-vitamin supplement uses. | 7 |
| Gylling et al. (2014) [27]         | colorectal cancer | Sweden; Nested case-control | PB | 331/662 | GC-MS / Plasma | M/F | 59.7 | Highest vs lowest | 1.01 (0.72-1.43) | Adjusting for country, sex, age at recruitment (in 5-year groups), educational attainment (in four groups), smoking status (never/former/current/missing), cotinine (quartiles defined among current smokers) and alcohol intake at recruitment (g/day). Adjusting for country, sex, age at recruitment (in 5-year groups), educational attainment (in four groups), smoking status (never/former/current/missing), cotinine (quartiles defined among current smokers) and alcohol intake at recruitment (g/day). | 8 |
| Fanidi et al. (2014) [28]          | esophagus cancer | EPIC; Nested case-control | PB | 74/944 | HPLC / Plasma | M/F | 62 (all cases, including head, neck and esophagus) | Quartile Q4 vs Q1 | 1.19 (0.51-2.77) | Adjusted for age, gender, BMI, education, smoking pack-years, alcohol drinking frequency, H. pylori infection (in stomach cancer analyses), hepatitis B virus surface antigen (in liver cancer analyses), and plasma aflatoxin B1 levels (in liver cancer analyses); further adjusted for the other two plasma micronutrients in quintile distribution. (folate, vitamin B12) | 8 |
| Chang et al. (2015) [29]           | gastric Cancer | China; case-control | PB | 200/409 | Chemiluminescent immunoassay / Plasma | M/F | 62.8 | Quartile >13.1 vs ≤6.7 | 1.12 (0.64-1.96) | Adjusted for age, gender, baseline BMI, ever had colonoscopy, smoking, physical activity (min/wk of moderate or strenuous activity), hormone replacement therapy, red blood cell folate, plasma vitamin B-12, and plasma pyridoxal-5'-phosphate. Adjusted for age, gender, body mass index, systolic blood pressure, creatinine, high sensitivity C-reactive protein, serum total cholesterol, smoking and drinking habits and B-vitamin supplement uses. | 7 |
| First author, (year of publication) | Cancer type | Country; study design | Source of control | Case/Control | Method of measurement / Type of homocysteine | Gender | Median or mean age of (y) | Contrast (highest vs. lowest) (μmol/L) | Adjusted OR (95% CI) (highest vs. lowest) | Adjustment | Quality score |
|------------------------------------|-------------|-----------------------|-------------------|--------------|---------------------------------|--------|-----------------|--------------------------------|--------------------------------------|----------------|----------------|
| Chang et al. (2015) [29]           | esophagus cancer | China; case-control   | PB                | 206/409      | Chemiluminescent immunoassay/ Plasma | M/F    | 60.5            | Quartile >13.1 vs ≤6.7 | 1.54 (0.87-2.72)                             | Adjusted for age, gender, BMI, education, smoking pack-years, alcohol drinking frequency, H. pylori infection (in stomach cancer analyses), hepatitis B virus surface antigen (in liver cancer analyses), and plasma aflatoxin B1 levels (in liver cancer analyses); further adjusted for the other two plasma micronutrients in quintile distribution. (folate, vitamin B12) | 7               |
| Miranti et al. (2017) [30]         | non-cardia gastric adenocarcinoma | Finland; Nested case-control | PB            | 127/326       | HPLC / Serum                  | M      | 58              | Quartile >15.6 vs <11.0 | 1.16 (0.63-2.13)                             | Adjusted for age, BMI, number of cigarettes smoked, years of cigarette smoking, educational attainment, alcohol consumption, energy intake, fruits and vegetables. | 8               |
| Miranti et al. (2017) [30]         | esophagogastric junctional adenocarcinoma | Finland; Nested case-control | PB            | 46/326        | HPLC / Serum                  | M      | 59              | Quartile >15.6 vs <11.0 | 0.85 (0.30-2.44)                             | Adjusted for age, BMI, number of cigarettes smoked, years of cigarette smoking, educational attainment, alcohol consumption, energy intake, fruits and vegetables. | 8               |
| Miranti et al. (2017) [30]         | esophageal squamous cell carcinoma | Finland; Nested case-control | PB            | 60/326        | HPLC / Serum                  | M      | 57              | Quartile >15.6 vs <11.0 | 1.35 (0.56-3.33)                             | Adjusted for age, BMI, number of cigarettes smoked, years of cigarette smoking, educational attainment, alcohol consumption, energy intake, fruits and vegetables. | 8               |

Abbreviations: EPIC: the European Prospective Investigation into Cancer and Nutrition; vs: versus; M: male; F: female; PB: population-based; HB: hospital-based; HPLC: High Performance Liquid Chromatography; GC-MS: gas chromatography-mass spectrometry; FPIA: fluorescence polarization immunoassay.
stability and function of genes. When the promoter region of the tumor suppressor gene is hypermethylated, its expression can be inhibited, resulting in genetic mutation and increased cell proliferation. Additionally, studies have demonstrated that hypermethylation could be in the promoter region of mismatch repair gene hMLH1 in patients with sporadic colorectal cancer with microsatellite instability, which can be used as a basis for treatment and prognosis [39, 40]. All of these indicate that methylation is closely related to tumorigenesis and that homocysteine can be used as a marker of methylation status invivo.

| Study ID | ES (95% CI) | Weight |
|----------|-------------|---------|
| I Kato et al. (1999) | 1.72 (0.83, 3.57) | 1.67 |
| Pufuete et al. (2003) | 1.55 (0.21, 11.16) | 0.22 |
| Van Guelpen, Hultdin, Johansson et al. (2006) | 1.12 (0.63, 1.99) | 2.68 |
| Stein Emil Vollset et al. (2007) | 0.87 (0.52, 1.44) | 3.42 |
| Lina Wang et al. (2007) | 1.82 (1.20, 2.75) | 5.16 |
| Weinstein et al. (2008) | 1.22 (0.68, 2.17) | 2.63 |
| Marchand et al. (2009) | 1.00 (0.56, 1.79) | 2.63 |
| Miller et al. (2013) | 1.46 (1.05, 2.04) | 8.04 |
| F.-F. Chiang et al. (2014) | 1.29 (1.14, 1.47) | 5.14 |
| Gyling et al (2014) | 1.01 (0.72, 1.43) | 7.54 |
| Fanidi et al. (2014) | 1.19 (0.51, 2.77) | 1.24 |
| Chang et al.[1] (2015) | 1.12 (0.64, 1.96) | 2.83 |
| Chang et al.[2] (2015) | 1.54 (0.87, 2.72) | 2.73 |
| Miranti et al.[1] (2017) | 1.16 (0.63, 2.13) | 2.39 |
| Miranti et al.[2] (2017) | 0.85 (0.30, 2.44) | 0.81 |
| Miranti et al.[3] (2017) | 1.35 (0.56, 3.33) | 1.12 |
| Overall (I-squared = 0.0%, p = 0.798) | 1.27 (1.15, 1.39) | 100.00 |

**Figure 2:** Forest plot of highest versus lowest categories of homocysteine on digestive cancer risk. The squares and horizontal lines correspond to the study-specific ORs and 95% CI. The area of the squares reflects the weight. The diamond represents the summary OR and 95% CI. ORs, Odds ratios; CI, confidence interval.

**Figure 3:** Dose-response analyses of the linear association between homocysteine and the risk of digestive cancer.

**Figure 4:** Begg’s funnel plot for publication bias test of the relationship between homocysteine and digestive cancer risk.
Figure 5: Influence analysis of the pooled relative risk coefficients on the relationship between homocysteine and digestive cancer risk. The two ends of the dotted lines represent the 95% CI.

Table 2: Stratified analyses of homocysteine and digestive cancer risk.

| Group                  | No. of comparisons | Summary OR (95% CI) | P    | I² (%) |
|------------------------|--------------------|---------------------|------|--------|
| Total                  | 16                 | 1.27(1.15-1.39)     | 0.798| 0.0    |
| **Design**             |                    |                     |      |        |
| Nested case-control    | 11                 | 1.16(0.99-1.37)     | 0.851| 0.0    |
| Case-control           | 5                  | 1.33(1.18-1.49)     | 0.548| 0.0    |
| **Location**           |                    |                     |      |        |
| Asia                   | 4                  | 1.33(1.18-1.49)     | 0.386| 1.2    |
| America                | 3                  | 1.38(1.05-1.80)     | 0.440| 0.0    |
| Europe                 | 9                  | 1.06(0.87-1.30)     | 0.990| 0.0    |
| **Cancer type**        |                    |                     |      |        |
| Esophageus cancer      | 4                  | 1.31(0.89-1.93)     | 0.797| 0.0    |
| Gastric cancer         | 4                  | 1.27(0.98-1.64)     | 0.152| 43.3   |
| Colorectal cancer      | 8                  | 1.27(1.14-1.41)     | 0.780| 0.0    |
| **Source of control**  |                    |                     |      |        |
| PB                     | 14                 | 1.24(1.08-1.43)     | 0.682| 0.0    |
| HB                     | 2                  | 1.29(1.14-1.47)     | 0.857| 0.0    |
| **Material**           |                    |                     |      |        |
| Plasma                 | 11                 | 1.27(1.15-1.40)     | 0.533| 0.0    |
| Serum                  | 5                  | 1.26(0.91-1.74)     | 0.853| 0.0    |
| **Method of measurement** |                |                     |      |        |
| HPLC                   | 9                  | 1.29(1.16-1.44)     | 0.953| 0.0    |
| GC-MS                  | 2                  | 0.96(0.73-1.28)     | 0.634| 0.0    |
| FPIA                   | 2                  | 1.15(0.66-2.00)     | 0.758| 0.0    |
| Other method           | 3                  | 1.53(1.15-1.39)     | 0.393| 0.0    |
| **Control definition** |                    |                     |      |        |
| Healthy population     | 5                  | 1.28(1.14-1.44)     | 0.850| 0.0    |
| Population free from cancer |      | 11                | 1.25(1.07-1.47) | 0.431| 1.1    |

Abbreviations: PB: population-based; HB: hospital-based; HPLC: High Performance Liquid Chromatography; GC-MS: gas chromatography-mass spectrometry; FPIA: fluorescence polarization immunoassay.
However, the mechanisms by which elevated homocysteine enhances digestive tract carcinogenesis have not yet been clearly elucidated. Homocysteine is a non-protein–forming sulfur amino acid whose metabolism is of great importance in remethylation, in which SAM plays the part of a universal methyl donor to various acceptors [41]. A byproduct of the remethylation reaction is S-adenosylhomocysteine (SAH), which is hydrolyzed and subsequently regenerates homocysteine. It should be noted that this reaction is reversible with equilibrium dynamics that have a preference for SAH synthesis to hydrolysis. The reason why this reaction actually proceeds in the hydrolytic direction is that the product can be removed efficiently [42]. If the homocysteine cannot be removed effectively, the SAH will accumulate which has a negative influence on the methyltransferase reaction [43]. Increasing concentrations of homocysteine were found to be linked to increased concentrations of SAH. With the increase of SAH levels, intracellular lymphocyte SAH levels increase, which results in hypomethylation of lymphocyte DNA [44]. All the above suggests that elevation of homocysteine levels may have a negative and indirect influence on the cellular methylation reactions that were found to have a close link to the pathogenesis of cancer.

As far as we know, this meta-analysis is the first to explore the relationship between homocysteine and digestive cancer risk by the method of dose-response analysis. Additionally, there was no significant heterogeneity or publication bias observed in our analysis, which suggested that the articles included were compatible for our meta-analysis despite including a variety of studies concerning different populations, living environments, family history, habits, and customs. However, we must acknowledge the limitations of the meta-analysis. First, unpublished studies were not included in our meta-analysis, which can result in publication bias although the statistical data did not reflect this. Second, only studies published in English met our inclusion criterion, so meaningful data may have been ignored. Additionally, only 13 comparisons were contained in the meta-analysis, which might, to a certain extent, have affected the reliability of the results.

5. Conclusion

In conclusion, our meta-analysis suggested that, with higher concentration of homocysteine, the incidence of digestive tract cancer increased despite the limitations of our meta-analysis. Further studies with larger sample size and more integral data are necessary to confirm our finding.

Data Availability

The data used to support the findings of our study have been deposited in PubMed. All 13 articles included in our meta-analysis can be found in PubMed; the PMID are 10206314, 12730865, 16638790, 18006931, 17438114, 18990766, 19661077, 19661077, 24280101, 25063522, 24975698, 25607998, and 28568053, respectively.

Conflicts of Interest

The authors declare that they have no conflicts of interest concerning this article.

Authors’ Contributions

Lingjun Zhu and Wei Wang conceived and designed the experiments. Peng Ni, Chujun Li, and Anjing Ren analyzed the data. Jun Xu and Shanwen Sun contributed analysis tools. Jun Xu, Shanwen Sun, and Xin Zhao wrote the first draft of the manuscript. All authors reviewed the manuscript. Thanks are due to the first corresponding author Lingjun Zhu for designing the study. Jun Xu, Xin Zhao, and Shanwen Sun contributed equally to this work.

Acknowledgments

This study was partially supported by the National Natural Science Foundation of China (NSFC 81472634), Jiangsu Province’s Key Provincial Talents Program (ZDRCA2016089), and Six Talent Peaks Project in Jiangsu Province (2013-WSN-034).

References

[1] J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, pp. E359–E386, 2015.
[2] P. M. Das and R. Singal, “DNA methylation and cancer,” Journal of Clinical Oncology, vol. 22, pp. 4632–4642, 2004.
[3] J. Frigola, X. Solé, M. F. Paz et al., “Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer,” Human Molecular Genetics, vol. 14, no. 2, pp. 319–326, 2005.
[4] T. Waki, G. Tamura, T. Tsuchiya, K. Sato, S. Nishizuka, and T. Motoyama, “Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia,” The American Journal of Pathology, vol. 161, no. 2, pp. 399–403, 2002.
[5] L. Hannibal and H. J. Blom, “Homocysteine and disease: Causal associations or epiphenomenons?” Molecular Aspects of Medicine, vol. 53, pp. 36–42, 2017.
[6] J. Selhub, “Homocysteine metabolism,” Annual Review of Nutrition, vol. 19, pp. 217–246, 1999.
[7] Y.-I. Kim, “Folate and DNA methylation: a mechanistic link between folate deficiency and colorectal cancer?” Cancer Epidemiology, Biomarkers & Prevention, vol. 13, no. 4, pp. S11–S19, 2004.
[8] S. E. Vollset, J. Iglund, M. Jenab et al., “The association of gastric cancer risk with plasma folate, cobalamin, and Methylenetetrahydrofolate reductase polymorphisms in the European prospective investigation into cancer and nutrition,” Cancer Epidemiology, Biomarkers & Prevention, vol. 16, no. 11, pp. 2416–2424, 2007.
[9] T. Qin, M. Du, H. Du, Y. Shu, M. Wang, and L. Zhu, “Folic acid supplements and colorectal cancer risk: meta-analysis of randomized controlled trials,” Scientific Reports, vol. 5, no. 1, 2015.
[10] E. Benito, A. Stiggelbout, F. X. Bosch et al., “Nutritional factors in colorectal cancer risk: A case-control study in majorca,” *International Journal of Cancer*, vol. 94, no. 2, pp. 161–167, 1999.

[11] T.-Y. Lee, E.-P. Chiang, Y.-T. Shih, H.-Y. Lane, J.-T. Lin, and C.-Y. Wu, “Lower serum folate is associated with development and invasiveness of gastric cancer,” *World Journal of Gastroenterology*, vol. 20, no. 32, pp. 11313–11320, 2014.

[12] Q. Xiao, N. D. Freedman, J. Ren, A. R. Hollenbeck, C. C. Abnet, and Y. Park, “Intakes of folate, methionine, vitamin B6, and vitamin B12 with risk of esophageal and gastric cancer in a large cohort study,” *British Journal of Cancer*, vol. 110, no. 5, pp. 1328–1333, 2014.

[13] L. Sharp, A.-E. Carsin, M. M. Cantwell, L. A. Anderson, and L. J. Murray, “Intakes of dietary folate and other B vitamins are associated with risks of esophageal adenocarcinoma, Barrett’s esophagus, and reflux esophagitis,” *Journal of Nutrition*, vol. 143, no. 12, pp. 1966–1973, 2013.

[14] B. Gylling, R. Myte, A. Ulvik et al., “One-carbon metabolite ratios as functional B-vitamin markers and in relation to colorectal cancer risk,” *International Journal of Cancer*, 2018.

[15] D. G. Weir and J. M. Scott, “Homocysteine as a risk factor for cardiovascular and related disease: Nutritional implications,” *Nutrition Research Reviews*, vol. 11, no. 2, pp. 311–338, 1998.

[16] Homocysteine Studies Collaboration, “Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis,” *The Journal of the American Medical Association*, vol. 288, no. 16, pp. 2015–2022, 2002.

[17] L. Wang, Q. Ke, W. Chen et al., “Polymorphisms of MTHFD, plasma homocysteine levels, and risk of gastric cancer in a high-risk Chinese population,” *Clinical Cancer Research*, vol. 13, no. 8, pp. 2526–2532, 2007.

[18] J. W. Miller, S. A. Beresford, M. L. Neuhausser et al., “Homocysteine, cysteine, and risk of incident colorectal cancer in the Women’s Health Initiative observational cohort,” *American Journal of Clinical Nutrition*, vol. 97, no. 4, pp. 827–834, 2013.

[19] B. Van Guelpen, J. Hultdin, I. Johansson et al., “Low folate levels may protect against colorectal cancer,” *Gut*, vol. 55, no. 10, pp. 1461–1466, 2006.

[20] S. J. Weinstein, D. Albanes, J. Selhub et al., “One-carbon metabolism biomarkers and risk of colon and rectal cancers,” *Cancer Epidemiology, Biomarkers & Prevention*, vol. 17, no. 11, pp. 3233–3240, 2008.

[21] S. M. Collin, C. Metcalfe, H. Refsum et al., “Circulating Folate, Vitamin B12, Homocysteine, Vitamin B12 Transport Proteins, and Risk of Prostate Cancer: a Case-Control Study, Systematic Review, and Meta-analysis,” *Cancer Epidemiology, Biomarkers & Prevention*, vol. 19, no. 6, pp. 1632–1642, 2010.

[22] W. Xu, Y. Cheng, and H. Zhu, “Evaluation of an Association of Blood Homocysteine Levels with Gastric Cancer Risk from 27 Case-Control Studies,” *Medicine (United States)*, vol. 95, no. 20, Article ID e5700, 2016.

[23] I. Kato, A. M. Dinistrian, M. Schwartz et al., “Serum folate, homocysteine and colorectal cancer risk in women: A nested case-control study,” *British Journal of Cancer*, vol. 79, no. 11-12, pp. 1917–1922, 1999.

[24] M. Pfuteule, R. Al-Ghñaim, A. J. M. Leather et al., “Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: A case control study,” *Gastroenterology*, vol. 124, no. 5, pp. 1240–1248, 2003.

[25] L. Le Marchand, K. K. White, A. M. Y. Nomura et al., “Plasma levels of B vitamins and colorectal cancer risk: The multiethnic cohort study,” *Cancer Epidemiology, Biomarkers & Prevention*, vol. 18, no. 8, pp. 2195–2201, 2009.

[26] F.-F. Chiang, H.-M. Wang, Y.-C. Lan, M.-H. Yang, S.-C. Huang, and Y.-C. Huang, "High homocysteine is associated with increased risk of colorectal cancer independently of oxidative stress and antioxidant capacities," *Clinical Nutrition*, vol. 33, no. 6, pp. 1054–1060, 2014.

[27] B. Gylling, B. Van Guelpen, J. Schneede et al., “Low folate levels are associated with reduced risk of colorectal cancer in a population with low folate status,” *Cancer Epidemiology, Biomarkers & Prevention*, vol. 23, no. 10, pp. 2136–2144, 2014.

[28] A. Fanidi, C. Relton, P. M. Ueland et al., “A prospective study of one-carbon metabolism biomarkers and cancer of the head and neck and esophagus,” *International Journal of Cancer*, vol. 136, no. 4, pp. 915–927, 2015.

[29] S.-C. Chang, B. Y. Goldstein, L. Mu et al., “Plasma folate, vitamin B12, and homocysteine and cancers of the esophagus, stomach, and liver in a Chinese population,” *Nutrition and Cancer*, vol. 67, no. 2, pp. 212–223, 2015.

[30] E. H. Miranti, R. Stolzenberg-Solomon, S. J. Weinstein et al., “Low vitamin B12 increases risk of gastric cancer: A prospective study of one-carbon metabolism nutrients and risk of upper gastrointestinal tract cancer,” *International Journal of Cancer*, vol. 141, no. 6, pp. 1120–1129, 2017.

[31] A. Stang, “Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses,” *European Journal of Epidemiology*, vol. 25, no. 9, pp. 603–605, 2010.

[32] J. P. T. Higgins and S. G. Thompson, “Quantifying heterogeneity in a meta-analysis,” *Statistics in Medicine*, vol. 21, no. 11, pp. 1539–1558, 2002.

[33] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” *British Medical Journal*, vol. 327, pp. 557–560, 2003.

[34] C. B. Begg and M. Mazumdar, “Operating characteristics of a rank correlation test for publication bias,” *Biometrics*, vol. 50, no. 4, pp. 1088–1101, 1995.

[35] A. E. Stuck, L. Z. Rubenstein, and D. Wieland, “Bias in meta-analysis detected by a simple, graphical test,” *British Medical Journal*, vol. 316, no. 7129, pp. 469–471, 1998.

[36] S. Greenland and M. P. Longnecker, “Methods for trend estimation from summarized dose-response data, with applications to meta-analysis,” *American Journal of Epidemiology*, vol. 135, no. 11, pp. 1301–1309, 1992.

[37] N. Orsini, R. Bellodco, and S. Greenland, “Generalized least squares for trend estimation of summarized dose-response data,” *Stata Journal*, vol. 6, no. 1, pp. 40–57, 2006.

[38] M. Kulis and M. Esteller, “DNA methylation and cancer,” *Advances in Genetics*, vol. 70, pp. 27–56, 2010.

[39] F. D. Lay, Y. Liu, T. K. Kelly et al., “The role of DNA methylation in directing the functional organization of the cancer epigenome,” *Genome Research*, vol. 25, no. 4, pp. 467–477, 2015.

[40] S. B. Baylin and P. A. Jones, “A decade of exploring the cancer epigenome—biological and translational implications,” *Nature Reviews Cancer*, vol. 11, pp. 726–734, 2011.

[41] J. D. Finkelstein, “Pathways and regulation of homocysteine metabolism in mammals,” *Seminars in Thrombosis and Hemostasis*, vol. 26, no. 3, pp. 219–225, 2000.

[42] J. D. Finkelstein, “The metabolism of homocysteine: pathways and regulation,” *European Journal of Pediatrics*, vol. 157, suppl 2, pp. S40–S44, 1998.
[43] S. J. James, S. Melnyk, M. Pogribna, I. P. Pogribny, and M. A. Caudill, "Elevation in S-Adenosylhomocysteine and DNA hypomethylation: Potential epigenetic mechanism for homocysteine-related pathology," Journal of Nutrition, vol. 132, no. 8, pp. 2361s–2366s, 2002.

[44] P. Yi, S. Melnyk, M. Pogribna, I. P. Pogribny, R. J. Hine, and S. J. James, "Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation," The Journal of Biological Chemistry, vol. 275, no. 38, pp. 29318–29323, 2000.